Where to inject Zepbound: stomach, thigh or arm, and how to rotate sites

Tirzepatide is injected under the skin once a week, and Lilly’s FDA-approved instructions for Zepbound and Mounjaro name the same three places: the stomach, the thigh and the back of the upper arm. The prescribing information adds one rule that applies everywhere: rotate injection sites with each dose. All three sites gave similar drug exposure, so the choice comes down to comfort and who is doing the injecting. What differs between devices is how the dose gets in.

Where to inject Zepbound and Mounjaro

All three are subcutaneous, meaning into the fat layer under the skin. Lilly’s safety summary says not to inject into a muscle or a vein. If you take insulin with Mounjaro, the label says the two can go in the same body area but not right next to each other, and must never be mixed in one injection.

Does it matter where you inject?

For how much drug reaches your blood, the label says no. “Similar exposure was achieved” with injection in the abdomen, thigh or upper arm, so there is no labeled reason to favor one site for better results. Your healthcare provider can help you choose, and the pen instructions say exactly that.

How to rotate Zepbound injection sites

The pen and KwikPen instructions say to change the injection site each week. You may stay in the same body area, as long as you choose a different spot within it. The vial instructions explain why: rotating lowers the risk of lipodystrophy, which is pits or thickening in the skin, and localized cutaneous amyloidosis, which is lumps at the injection site.

The vial instructions also list places to skip:

• Skin with pits, thickening or lumps
• Skin that is tender, bruised, scaly or hard
• Scars or damaged skin

Keeping a note of each week’s site makes rotation easier. The dose tracker does this, and the general injection sites guide includes a simple 8-week rotation pattern that fits a weekly drug.

Pen, KwikPen or vial: what changes

Lilly sells Zepbound in three forms, and the label also lists a multi-dose vial. The sites are identical, but the technique is not. The label calls for training on the specific form you receive, and again if it changes.

A few details people commonly ask about:

• Check the liquid first. It should be clear and colorless to slightly yellow. The label says not to use it if you see particles or discoloration.
• Pen temperature. The instructions say it is not necessary to warm the pen before injecting, and that air bubbles in the pen are normal.
• Pen mishaps. If the button is pressed before the gray base cap comes off, the instructions say to leave the cap on, throw the pen away and get a new one. Once removed, the cap should not go back on. A drop of liquid on the needle tip is normal.
• Extra clicks. Some people hear a soft click just before the second loud click. That is normal, and the pen stays on the skin until the second loud click.
• Multi-dose vial. Each holds 4 doses of 0.6 mL, with a new syringe and needle every week. The vial instructions say not to mix Zepbound with any other medicine.
• KwikPen leftovers. Some medicine stays in the pen after the fourth dose. The instructions say to throw the pen away with it, not to inject the leftover, and not to transfer medicine from the pen into a syringe.
• KwikPen sharing. The label warns against sharing one between people, even with a new needle, because of the risk of blood-borne infection.
• Vision problems. The label says the KwikPen is not recommended for self-injection by people who are visually impaired. The pen instructions say not to use the pen without help from someone trained on it.
• Vial units. A single-dose vial dose is 0.5 mL regardless of strength, and a multi-dose vial dose is 0.6 mL. On a U-100 insulin syringe those are the 50-unit and 60-unit lines. Compounded tirzepatide is different, and the tirzepatide units calculator handles that case.

How to store Zepbound

Storage rules differ by device. Every form should be kept from freezing, heat and light, in the original carton. If Zepbound has been frozen, the label says not to use it.

An opened KwikPen or multi-dose vial is discarded after a total of 30 days at room temperature, 30 days after first use, or 4 weekly doses, whichever comes first, even if medicine is left.

After the injection

If you see a drop of blood or liquid, the instructions say to press the site lightly with gauze or a cotton ball and not to rub it. Used pens, pen needles and syringes go straight into an FDA-cleared sharps container. If you do not have one, a heavy-duty plastic household container with a tight, puncture-resistant lid can be used. The instructions say not to recycle it, and to follow local rules when it is nearly full.

What to watch for at the injection site

Injection site reactions affected 6% to 8% of people on Zepbound in the weight trials, against 2% on placebo. They include bruising, redness, itching, pain and rash. Worth reporting to your prescriber are spreading redness, warmth or swelling, a lump that persists or grows, or skin changes at a site you use often, which is what rotation is meant to prevent.

Swelling of the face, lips, tongue or throat, or trouble breathing, is an emergency. Lilly’s safety summary says to stop Zepbound and get medical help right away. The tirzepatide side effects guide covers the drug’s other warnings, including the boxed thyroid warning and who should not use it. The dose itself is set by your prescriber, and the tirzepatide dosage chart shows the labeled schedule.